The Food and Drug Administration released a draft of rules that companies should follow to develop cannabis-derived drugs — a new category that has exploded with few federal laws to govern it.
The guidelines cover drugs and treatments containing cannabis oil and other compounds found in the plant, the agency said on Tuesday. They include references for calculating weights for oral dosages and online resources related to clinical trials for cannabis-derived products.
The draft draws on a 2019 public hearing where industry representatives expressed concern about inaccurate or misleading labels for products with CBD, a cannabis extract,
To read more, click on https://www.bloomberg.com/news/articles/2020-07-21/fda-releases-initial-guidelines-for-cannabis-derived-drugs
